CN117018125A - Anti-fatigue pharmaceutical composition - Google Patents
Anti-fatigue pharmaceutical composition Download PDFInfo
- Publication number
- CN117018125A CN117018125A CN202311296744.8A CN202311296744A CN117018125A CN 117018125 A CN117018125 A CN 117018125A CN 202311296744 A CN202311296744 A CN 202311296744A CN 117018125 A CN117018125 A CN 117018125A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- fatigue
- northeast
- alpine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 71
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 54
- 240000008042 Zea mays Species 0.000 claims abstract description 19
- 235000007244 Zea mays Nutrition 0.000 claims abstract description 19
- 229940089639 cornsilk Drugs 0.000 claims abstract description 19
- 239000001231 zea mays silk Substances 0.000 claims abstract description 19
- 241000222640 Polyporus Species 0.000 claims abstract description 15
- 240000008866 Ziziphus nummularia Species 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 11
- 241000222684 Grifola Species 0.000 claims description 10
- 240000002547 Rosa roxburghii Species 0.000 claims description 10
- 235000000640 Rosa roxburghii Nutrition 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 10
- 241000234282 Allium Species 0.000 claims description 7
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 27
- 244000291564 Allium cepa Species 0.000 abstract description 21
- 235000010167 Allium cepa var aggregatum Nutrition 0.000 abstract description 21
- 239000000203 mixture Substances 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 17
- 241000220317 Rosa Species 0.000 abstract description 9
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000009182 swimming Effects 0.000 description 32
- 206010016256 fatigue Diseases 0.000 description 27
- 239000008280 blood Substances 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 25
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 235000000346 sugar Nutrition 0.000 description 10
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 241001180876 Saposhnikovia Species 0.000 description 7
- 229920002527 Glycogen Polymers 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229940096919 glycogen Drugs 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 239000000969 carrier Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- -1 flavonoid compound Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 235000001270 Allium sibiricum Nutrition 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- ZCSHACFHMFHFKK-UHFFFAOYSA-N 2-methyl-1,3,5-trinitrobenzene;2,4,6-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)C1NC([N+]([O-])=O)NC([N+]([O-])=O)N1.CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ZCSHACFHMFHFKK-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000161286 Allium victorialis Species 0.000 description 1
- 235000011644 Allium victorialis Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 241000407039 Heracleum moellendorffii Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000229179 Ledebouriella Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- XDROKJSWHURZGO-UHFFFAOYSA-N isopsoralen Natural products C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention discloses a pharmaceutical composition for resisting fatigue, and relates to the technical field of traditional Chinese medicine compositions. The medicinal composition provided by the invention comprises the Changbai mountain shallot, northeast radix sileris, corn silk, polyporus, roxburgh rose and wild jujube seed, and has obvious anti-fatigue effect through reasonable compatibility, namely scientific proportion, natural and safe components and no toxic or side effect.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a medicine composition for resisting fatigue.
Background
Fatigue is a protective physiological phenomenon of organism for avoiding tissue damage caused by excessive movement and excessive fatigue, and the fatigue is often accompanied with extremely tired feeling, which reduces physiological performance of organism and causes physical and mental discomfort, so that people feel tired, weak and seriously influence metabolic efficiency, immunity and resistance of various organs of human body. Fatigue is an inevitable problem in daily life and work, however, excessive fatigue can have a series of negative effects on health, and therefore, reduction and prevention of fatigue are the research directions of interest.
At present, the body fatigue can be relieved by means of resting, nutrition supplementing, drug treatment and the like, and certain foods, health products, traditional Chinese medicine compositions and the like have certain anti-fatigue effects, and most of the anti-fatigue effects can relieve the body fatigue by promoting the metabolism and the immune function of a human body.
For example, chinese patent application CN200910312277.7 provides a pharmaceutical composition for anti-fatigue, which is prepared from the following raw materials in parts by weight: 5-15 parts of ginseng, 10-15 parts of curcuma zedoary, 5-15 parts of medlar, 5-15 parts of astragalus, 1-10 parts of polygonum multiflorum and 5-15 parts of ligusticum wallichii. Pharmacological experiments prove that the oral and external pharmaceutical composition has the anti-fatigue effect. Meanwhile, the pharmaceutical composition is prepared into an external preparation, and is applied to clinic in combination with massage, so that the fatigue syndrome caused by excessive mental labor, physical labor or long-term stress of the spirit can be improved, and the curative effects of symptoms such as insufficient energy, fatigue and sleepiness, listlessness, distraction, chest distress, palpitation, insomnia, amnesia and the like are remarkable.
For another example, chinese patent application CN201811318159.2 provides an anti-fatigue pharmaceutical composition, and a preparation method and use thereof, wherein the pharmaceutical composition comprises homoplantaginide and other anti-fatigue active ingredients, and preferably the other anti-fatigue active ingredients are selected from: rhodiola rosea glycoside, taurine, ginsenoside or gynostemma pentaphylla saponin. The pharmaceutical composition can obviously relieve the fatigue state of the body, can be widely applied to the prevention and treatment of sports fatigue, fatigue caused by sub-health, chronic fatigue and the like, and is safe without any toxic or side effect.
The herba Alii Fistulosi (Allium victorialis L.) is plant of Allium of Liliaceae, and is mainly distributed in natural protection region of Changbai mountain, and contains sulfur-containing compound, flavonoid compound, steroid, etc., and has hemostatic, analgesic, and fatigue relieving effects. Radix Ledebouriellae (Heracleum moellendorffii Hance) is an Umbelliferae plant, and its active ingredient angelicin has good artery dilating, i.e. blood circulation promoting, effects of dispelling pathogenic wind, eliminating dampness, detumescence, and relieving pain. Although the two raw materials have certain anti-fatigue effect, the anti-fatigue effect is not obvious in practical application, and the prior art does not optimize the composition containing the two components so as to obtain the anti-fatigue traditional Chinese medicine composition, so that the medicinal value of the composition cannot be fully utilized.
In view of the above, the invention has the advantages that the pharmacological actions of the chives and the radix sileris are fully exerted by screening the reasonable compatibility of the traditional Chinese medicine components, and the medicine composition with obvious anti-fatigue effect is obtained for people with easy fatigue.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition with an anti-fatigue effect, which aims at people easy to fatigue, improves the anti-fatigue effect, and has natural and safe components and no toxic or side effect.
In order to achieve the above object, the present invention has the following technical scheme:
in one aspect, the invention provides an anti-fatigue pharmaceutical composition comprising a Changbai mountain shallot, northeast radix sileris, corn silk, polyporus, rosa roxburghii and semen Ziziphi Spinosae.
Preferably, the anti-fatigue pharmaceutical composition comprises, by weight, 10-20 parts of Changbai mountain shallot, 10-20 parts of northeast radix sileris, 1-5 parts of corn silk, 1-5 parts of Polyporus, 1-5 parts of Rosa roxburghii and 0.1-3 parts of wild jujube seed.
Further preferably, the anti-fatigue pharmaceutical composition comprises, by weight, 12-18 parts of Changbai mountain shallot, 12-18 parts of northeast radix sileris, 1-3 parts of corn silk, 2-4 parts of Polyporus, 3-5 parts of Rosa roxburghii and 0.5-2 parts of wild jujube seed.
Most preferably, the anti-fatigue pharmaceutical composition comprises, by weight, 16 parts of Changbai mountain shallot, 16 parts of northeast radix sileris, 2 parts of corn silk, 3 parts of Polyporus, 4 parts of Rosa roxburghii and 1 part of semen Ziziphi Spinosae.
Preferably, in the anti-fatigue pharmaceutical composition, the mass ratio of the Changbai mountain shallot to the northeast radix sileris is 1:0.5-2.
Further preferably, in the anti-fatigue pharmaceutical composition, the mass ratio of the alpine onion to the northeast radix sileris is 1:1.
In another aspect, the present invention provides a method for preparing the above pharmaceutical composition for anti-fatigue, comprising the steps of:
decocting herba Alii Fistulosi, radix Saposhnikoviae, stigma Maydis, polyporus, fructus Rosae Normalis and semen Ziziphi Spinosae in water, mixing decoctions, concentrating, and drying to obtain antifatigue pharmaceutical composition.
Wherein the water includes, but is not limited to, purified water, potable water, ultrapure water, distilled water.
Preferably, the number of times of the decoction is 2 to 4 times, more preferably 3 times.
Preferably, the time of the decoction is 0.5-2h, more preferably 1h.
The concentration method comprises, but is not limited to, reduced pressure distillation, centrifugation and other common concentration methods in the field.
Such drying means include, but are not limited to, drying means common in the art such as baking, spray drying, lyophilization, and the like.
In still another aspect, the invention provides a medicament, wherein the active ingredients of the medicament are the traditional Chinese medicine composition.
The medicine can be prepared into administration dosage forms such as pills, capsules, granules, oral liquid, powder, tablets, troches, lozenges and the like, and the proper medicine carriers in the field can be selected according to different dosage forms.
The pharmaceutical carrier used may be solid, liquid or gaseous. Examples of solid carriers include lactose, kaolin, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid. Examples of liquid carriers include syrup, peanut oil, olive oil, and water. Examples of the gas carrier include carbon dioxide and nitrogen.
In preparing the composition in oral dosage form, any convenient pharmaceutical medium may be used. For example, water, ethanol, oil, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid formulations, such as suspensions; and carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, emulsifying agents, lubricants, binders, disintegrating agents can be employed to form oral solid preparations such as powders, capsules and tablets.
Tablets containing the present invention may be prepared by compression or molding, optionally with the use of one or more auxiliary ingredients or adjuvants. Tableting may be prepared by tableting the active ingredient in free-flowing form (e.g. powder or granules) in a suitable machine, optionally in admixture with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be molded in a suitable machine, i.e. a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g of active ingredient, and each pouch or capsule preferably contains from about 0.05mg to about 5g of active ingredient. For example, a formulation intended for oral administration to humans may contain about 0.5mg to about 5g of the active agent, mixed with an appropriate and convenient carrier material, which may constitute about 5% to 95% of the total composition. The unit dosage form will typically contain from about 1mg to about 2g of the active ingredient, typically 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg or 1000mg.
Pharmaceutical compositions of the invention suitable for parenteral administration may be prepared as aqueous solutions or suspensions of the active compounds. Suitable surfactants may be included, such as hydroxypropyl cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and oil mixtures thereof. In addition, preservatives may also be added to prevent detrimental growth of microorganisms.
The medicament of the invention may be in a form suitable for rectal administration wherein the carrier is a solid. The mixture is preferably formulated as a unit-dose suppository. Suitable carriers include cocoa butter and other materials commonly used in the art. Suppositories may be formed by first forming a mixture of the composition containing the softened or melted carrier, followed by cooling and shaping in a mold. In addition to the carrier ingredients, the pharmaceutical formulations may include one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surfactants, thickeners, lubricants, preservatives (including antioxidants), and the like. In addition, other adjuvants such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc., colorants, flavoring agents, etc., can be added.
The beneficial effects of the invention are as follows:
(1) By selecting reasonable compatibility of traditional Chinese medicines, the anti-fatigue effect can be exerted more remarkably, and the compatibility effect of one or less components is better.
(2) The anti-fatigue effect is further improved through reasonable weight proportion.
(3) Animal experiments prove that the pharmaceutical composition provided by the invention can prolong the time of swimming in the absence of blood, improve the blood sugar and liver glycogen level of mice after swimming, reduce the generation of blood lactic acid and blood urea nitrogen, and has remarkable anti-fatigue effect.
(4) The formula of the invention is prepared by decocting natural traditional Chinese medicine components in water, is safe to use, has no toxic or side effect, and is applicable to a wider range of people.
Detailed Description
In order to make the technical means, the creation features, the achievement of the purpose and the effect of the present invention easy to understand, the present invention will be further elucidated with reference to the specific embodiments, but the following embodiments are only preferred embodiments of the present invention, not all of them. Based on the examples in the embodiments, those skilled in the art can obtain other examples without making any inventive effort, which fall within the scope of the invention.
In the following examples, unless otherwise specified, the methods of operation used were conventional, the equipment used was conventional, and the materials used in the examples were the same.
Example 1
A pharmaceutical composition for resisting fatigue comprises, by weight, 10 parts of Changbai mountain shallot, 20 parts of northeast radix sileris, 1 part of corn silk, 5 parts of Polyporus, 1 part of Rosa roxburghii and 3 parts of semen Ziziphi Spinosae.
The preparation method of the anti-fatigue pharmaceutical composition comprises the following steps:
taking the formula amount of the Changbai mountain shallot, the northeast cow divaricate saposhnikovia root, the corn silk, the grifola, the roxburgh rose and the wild jujube, adding purified water for decocting for 2 times, each time for 2 hours, combining the decoctions, centrifuging, concentrating, freeze-drying and drying to obtain the anti-fatigue pharmaceutical composition A1.
Example 2
A pharmaceutical composition for resisting fatigue comprises 12 parts of Changbai mountain cold shallot, 18 parts of northeast radix sileris, 1 part of corn silk, 4 parts of Polyporus, 3 parts of roxburgh rose and 2 parts of wild jujube seed according to parts by weight.
The preparation method of the anti-fatigue pharmaceutical composition comprises the following steps:
taking the formula amount of the Changbai mountain shallot, the northeast cow divaricate saposhnikovia root, the corn silk, the grifola, the roxburgh rose and the wild jujube, adding purified water for decoction for 3 times, each time for 1 hour, combining the decoction, centrifuging, concentrating and spray drying to obtain the anti-fatigue pharmaceutical composition A2.
Example 3
A pharmaceutical composition for resisting fatigue comprises, by weight, 16 parts of Changbai mountain shallot, 16 parts of northeast radix sileris, 2 parts of corn silk, 3 parts of Polyporus, 4 parts of Rosa roxburghii and 1 part of semen Ziziphi Spinosae.
The preparation method of the anti-fatigue pharmaceutical composition comprises the following steps:
taking the formula amount of the Changbai mountain shallot, the northeast cow divaricate saposhnikovia root, the corn silk, the grifola, the roxburgh rose and the wild jujube, adding purified water for decoction for 3 times, each time for 1 hour, combining the decoction, centrifuging, concentrating and spray drying to obtain the anti-fatigue pharmaceutical composition A3.
Example 4
A pharmaceutical composition for resisting fatigue comprises, by weight, 18 parts of Changbai mountain herba Alii Fistulosi, 12 parts of radix Ledebouriellae, 3 parts of stigma Maydis, 2 parts of Polyporus, 5 parts of fructus Rosae Normalis and 0.5 part of semen Ziziphi Spinosae.
The preparation method of the anti-fatigue pharmaceutical composition comprises the following steps:
taking the formula amount of the Changbai mountain shallot, the northeast cow divaricate saposhnikovia root, the corn silk, the grifola, the roxburgh rose and the wild jujube, adding purified water for decoction for 3 times, each time for 1 hour, combining the decoction, centrifuging, concentrating and spray drying to obtain the anti-fatigue pharmaceutical composition A4.
Example 5
A pharmaceutical composition for resisting fatigue comprises, by weight, 20 parts of Changbai mountain herba Alii Fistulosi, 10 parts of radix Ledebouriellae, 5 parts of stigma Maydis, 1 part of Polyporus, 5 parts of fructus Rosae Normalis and 0.1 part of semen Ziziphi Spinosae.
The preparation method of the anti-fatigue pharmaceutical composition comprises the following steps:
taking the formula amount of the Changbai mountain shallot, the northeast cow divaricate saposhnikovia root, the corn silk, the grifola, the roxburgh rose and the wild jujube, adding purified water for decocting for 4 times, each time for 0.5h, combining the decoctions, distilling under reduced pressure, and drying to obtain the anti-fatigue pharmaceutical composition A5.
Comparative example 1
A pharmaceutical composition for resisting fatigue comprises 8 parts of herba Alii Fistulosi in Changbai mountain, 22 parts of radix Ledebouriellae in northeast China, 0.5 part of stigma Maydis, 5.5 parts of Polyporus, 0.5 part of fructus Rosae Normalis and 3.5 parts of semen Ziziphi Spinosae in parts by weight.
The preparation method of the anti-fatigue pharmaceutical composition comprises the following steps:
taking the formula amount of the Changbai mountain shallot, the northeast cow divaricate saposhnikovia root, the corn silk, the grifola, the roxburgh rose and the wild jujube, adding purified water for decoction for 3 times, each time for 1 hour, combining the decoction, centrifuging, concentrating and spray drying to obtain the anti-fatigue pharmaceutical composition B1.
Comparative example 2
A pharmaceutical composition for resisting fatigue comprises 22 parts by weight of Changbai mountain shallot, 8 parts by weight of northeast radix sileris, 5.5 parts by weight of corn silk, 0.5 part by weight of Polyporus, 5.5 parts by weight of Rosa roxburghii and 0.05 part by weight of wild jujube seed.
The preparation method of the anti-fatigue pharmaceutical composition comprises the following steps:
taking the formula amount of the Changbai mountain shallot, the northeast cow divaricate saposhnikovia root, the corn silk, the grifola, the roxburgh rose and the wild jujube, adding purified water for decoction for 3 times, each time for 1 hour, combining the decoction, centrifuging, concentrating and spray drying to obtain the anti-fatigue pharmaceutical composition B2.
Comparative example 3
A pharmaceutical composition for anti-fatigue was different from example 3 in that it did not contain Changbaishan chives, and pharmaceutical composition B3 was prepared.
Comparative example 4
A pharmaceutical composition for anti-fatigue was different from example 3 in that it did not contain Ledebouriella sessilifolia, and pharmaceutical composition B4 was prepared.
Comparative example 5
A pharmaceutical composition for resisting fatigue is different from example 3 in that the mass ratio of the Changbai mountain shallot to the northeast radix sileris is 1:0.4, and the total mass of the Changbai mountain shallot and the northeast radix sileris is the same as that of example 3, so as to prepare a pharmaceutical composition B5.
Comparative example 6
A pharmaceutical composition for resisting fatigue is different from example 3 in that the mass ratio of the Changbai mountain shallot to the northeast radix sileris is 1:2.5, and the total mass of the Changbai mountain shallot and the northeast radix sileris is the same as that of example 3, so as to prepare a pharmaceutical composition B6.
Anti-fatigue animal experiment
1. Experimental drugs: the pharmaceutical compositions A1-A5 and B1-B6 obtained by the invention.
2. Experimental animals: SPF-grade Kunming male mice, weighing 18-22g.
3. Experimental method
3.1 pretreatment of animals: the mice were randomly divided into a normal control group, a swimming control group and a pharmaceutical composition group (low dose 1250mg/kg, medium dose 2500mg/kg, high dose 5000 mg/kg), 10 mice per group; the pharmaceutical composition group was filled with the pharmaceutical composition of the present invention 1 time per day for 2 weeks, and the normal control group and the swimming control group were filled with the same amount of distilled water.
3.2 swimming experiments:
before formal swimming, the mice were trained 5 times for swimming, and then subjected to an exhaustive swimming and 90min swimming experiment.
Exhaustive swimming: after one gastric lavage for 30min, the swimming control group and the pharmaceutical composition group are placed in a swimming device at 30 ℃ to begin to bear a load for 3%, and the time of swimming with exhaustion (the time when the mice are immersed in water for 30 s) is recorded.
Swimming for 90 min: the swimming control group and the pharmaceutical composition group are arranged in a swimming device at 30 ℃ for swimming for 90min after the last gastric lavage, and the normal control group does not swim; after swimming, immediately picking up the eyeballs of the mice to collect blood, centrifuging to collect serum, and measuring the blood sugar content, the lactic acid content, the blood urea nitrogen content and the liver glycogen content.
3.3 experimental results
Experimental data was analyzed by data analysis of variance using SPSS software and the results are shown in tables 1-2 below.
TABLE 1 time of exhaustive swimming
Note that: in comparison with the swimming control group,＜0.05，/>＜0.01。
the results in table 1 show that the time to exhaustive swimming is significantly prolonged after the mice are given the pharmaceutical composition of the invention. Compared with the swimming control group, the low dose group has obvious difference (P is less than 0.05) of the time of the exhaustive swimming, and compared with the swimming control group, the medium dose group and the high dose group have obvious difference (P is less than 0.01) of the time of the exclusive swimming, which indicates that the pharmaceutical composition provided by the invention has obvious refreshing and anti-fatigue effects.
TABLE 2 blood sugar, blood lactic acid, blood urea nitrogen and liver glycogen content in mice
Note that: in comparison with the normal control group,＜0.05，/>< 0.01; compared with swimming control group->＜0.05，/>＜0.01。
The results in table 2 show that the pharmaceutical composition of the present invention has a significant effect on blood glucose, blood lactic acid, blood urea nitrogen and liver glycogen content after swimming in mice. Compared with the normal control group, the blood sugar and liver glycogen content of the mice in the swimming control group are reduced, the blood lactic acid and blood urea nitrogen content are increased, and the difference is very remarkable. Compared with the swimming control group, the blood sugar and liver sugar content of the drug composition mice are increased, the blood lactic acid and blood urea nitrogen content are reduced, and particularly, the differences of the drug compositions A1-A5 compared with the swimming control group are obvious. The pharmaceutical composition provided by the invention can improve the blood sugar and liver glycogen level of mice after swimming, reduce the generation of blood lactic acid and blood urea nitrogen, and has remarkable anti-fatigue effect. The contents of blood sugar, blood lactic acid, blood urea nitrogen and liver sugar of the mice after swimming of the pharmaceutical compositions B1-B5 are different from those of the pharmaceutical compositions A1-A5 to a certain extent, so that the invention can exert more remarkable anti-fatigue effect by selecting reasonable compatibility and scientific proportion of traditional Chinese medicines, and is superior to the compatibility effect of one or less components.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, alternatives, and improvements that fall within the spirit and scope of the invention.
Claims (9)
1. A pharmaceutical composition for resisting fatigue is characterized by comprising herba Alii Fistulosi in Changbai mountain, radix Saposhnikoviae in northeast China, stigma Maydis, polyporus, fructus Rosae Normalis and semen Ziziphi Spinosae.
2. The pharmaceutical composition for anti-fatigue according to claim 1, wherein the pharmaceutical composition comprises, by weight, 10-20 parts of alpine onion, 10-20 parts of radix sileris, 1-5 parts of corn silk, 1-5 parts of grifola, 1-5 parts of rosa roxburghii and 0.1-3 parts of spina date seed.
3. The pharmaceutical composition for anti-fatigue according to claim 2, which comprises, by weight, 12-18 parts of alpine onion, 12-18 parts of northeast radix sileris, 1-3 parts of corn silk, 2-4 parts of grifola, 3-5 parts of rosa roxburghii and 0.5-2 parts of wild jujube seed.
4. The pharmaceutical composition for anti-fatigue according to claim 3, which comprises 16 parts of alpine onion, 16 parts of northeast radix sileris, 2 parts of corn silk, 3 parts of grifola, 4 parts of rosa roxburghii and 1 part of wild jujube seed according to parts by weight.
5. The pharmaceutical composition for anti-fatigue according to any one of claims 1 to 4, wherein the mass ratio of the alpine onion to the northeast radix sileris is 1:0.5-2.
6. The pharmaceutical composition for anti-fatigue according to claim 5, wherein the mass ratio of the alpine onion to the northeast radix sileris is 1:1.
7. A method for preparing the pharmaceutical composition for anti-fatigue according to any one of claims 1 to 6, comprising the steps of:
decocting herba Alii Fistulosi, radix Saposhnikoviae, stigma Maydis, polyporus, fructus Rosae Normalis and semen Ziziphi Spinosae in water, mixing decoctions, concentrating, and drying to obtain antifatigue pharmaceutical composition.
8. The preparation method according to claim 7, wherein the number of times of decoction is 2 to 4.
9. The method according to claim 7, wherein the time of the decoction is 0.5 to 2 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311296744.8A CN117018125B (en) | 2023-10-09 | 2023-10-09 | Anti-fatigue pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311296744.8A CN117018125B (en) | 2023-10-09 | 2023-10-09 | Anti-fatigue pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117018125A true CN117018125A (en) | 2023-11-10 |
| CN117018125B CN117018125B (en) | 2023-12-19 |
Family
ID=88645346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311296744.8A Active CN117018125B (en) | 2023-10-09 | 2023-10-09 | Anti-fatigue pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117018125B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1582980A (en) * | 2003-08-18 | 2005-02-23 | 上海药港生物技术有限公司 | Chinese medicinal composition for improving sleep and relaxing fatigue and its preparation |
| CN101069723A (en) * | 2007-05-25 | 2007-11-14 | 上海育生堂科技有限公司 | Oral liquor of anti-fatigue and intensifying immunity and preparing method |
| KR20130039116A (en) * | 2011-10-11 | 2013-04-19 | 이재학 | Oriental medicine extract for poultry, method for manufacturing the same, powdered preparation under the same method |
| CN109200241A (en) * | 2017-06-30 | 2019-01-15 | 陆文秀 | A kind of Chinese medicine composition for treating anxiety disorder |
| CN109294838A (en) * | 2018-11-05 | 2019-02-01 | 毕节市中药研究所 | A kind of formula and preparation method of strengthening the spleen and replenishing qi Rosa roxburghii Tratt health liquor |
| CN112891399A (en) * | 2019-11-19 | 2021-06-04 | 雷家荃 | Traditional Chinese medicine composition and application and preparation method thereof |
| WO2023100764A1 (en) * | 2021-12-03 | 2023-06-08 | 住友化学株式会社 | Composition for preventing, improving or alleviating symptoms relating to qi deficiency and/or blood deficiency |
-
2023
- 2023-10-09 CN CN202311296744.8A patent/CN117018125B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1582980A (en) * | 2003-08-18 | 2005-02-23 | 上海药港生物技术有限公司 | Chinese medicinal composition for improving sleep and relaxing fatigue and its preparation |
| CN101069723A (en) * | 2007-05-25 | 2007-11-14 | 上海育生堂科技有限公司 | Oral liquor of anti-fatigue and intensifying immunity and preparing method |
| KR20130039116A (en) * | 2011-10-11 | 2013-04-19 | 이재학 | Oriental medicine extract for poultry, method for manufacturing the same, powdered preparation under the same method |
| CN109200241A (en) * | 2017-06-30 | 2019-01-15 | 陆文秀 | A kind of Chinese medicine composition for treating anxiety disorder |
| CN109294838A (en) * | 2018-11-05 | 2019-02-01 | 毕节市中药研究所 | A kind of formula and preparation method of strengthening the spleen and replenishing qi Rosa roxburghii Tratt health liquor |
| CN112891399A (en) * | 2019-11-19 | 2021-06-04 | 雷家荃 | Traditional Chinese medicine composition and application and preparation method thereof |
| WO2023100764A1 (en) * | 2021-12-03 | 2023-06-08 | 住友化学株式会社 | Composition for preventing, improving or alleviating symptoms relating to qi deficiency and/or blood deficiency |
Non-Patent Citations (4)
| Title |
|---|
| HA NA KIM: "Heracleum moellendorffii roots inhibit the production of pro-inflammatory mediators through the inhibition of NF-κB and MAPK signaling, and activation of ROS/Nrf2/HO-1 signaling in LPS-stimulated RAW264.7 cells", BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 19, pages 1 - 10 * |
| YOUNG SOOK KIM: "Effects of Allium victorialis leaf extracts and its single compounds on aldose reductase, advanced glycation end products and TGF-β1 expression in mesangial cells", BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 13, pages 1 - 7 * |
| 王扬欣: "寒葱不同极性溶剂萃取物的活性成分分析及抗氧化活性研究", 延边大学农学学报, vol. 3, no. 1, pages 1 - 8 * |
| 蔡馨瑶: "东北牛防风果实精油生物活性研究", 人参研究, no. 5, pages 40 - 43 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117018125B (en) | 2023-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111035649B (en) | NMN + GLP compound nutritional supplement and preparation method and application thereof | |
| CN103007052A (en) | Compound dendrobium extract composition capable of delaying senility | |
| CN102670994A (en) | Composition capable of relieving physical fatigue and preparation method of composition | |
| CN105832794A (en) | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia | |
| CN102551046B (en) | Natural health composition for weight reduction and application of same | |
| CN106509887A (en) | Fatigue preventing health-care composition and a preparation method thereof | |
| CN112546167A (en) | Traditional Chinese medicine composition with spleen invigorating and dampness removing functions and preparation method and application thereof | |
| WO2021109511A1 (en) | Anti-fatigue composition and preparation method therefor | |
| CN105708970B (en) | A kind of health food with function of blood sugar reduction | |
| CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
| CN101879264A (en) | Chinese medicinal composition for reducing blood uric acid | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN103006822B (en) | Application of American ginseng in preparing medicament for preventing and treating alcoholic liver injury | |
| CN116158529A (en) | Functional food composition with auxiliary uric acid reducing and gout relieving effects | |
| CN107188984B (en) | Polysaccharide composition and preparation method and application thereof | |
| CN113209166A (en) | Anti-aging traditional Chinese medicine composition containing nicotinamide mononucleotide and preparation method thereof | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN117018125B (en) | Anti-fatigue pharmaceutical composition | |
| CN105395702A (en) | Composition with hangover alleviating, liver protecting and anti-fatigue efficacy and application thereof | |
| CN102784230B (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN104055115B (en) | A kind of health products containing agate coffee, the stem of noble dendrobium and Panax Japonicus Var. Major and preparation method thereof | |
| CN104173745B (en) | A kind of anaesthetic of healthcare | |
| CN102370716A (en) | Health-preserving health-care medicine of gynostemma pentaphylla and multiflower knotweed root | |
| CN106360716A (en) | Traditional Chinese medicinal composition for improving body immunity and sleep, and preparation method thereof | |
| CN112022966A (en) | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |